Working… Menu
Trial record 10 of 115 for:    cancer | butyrate

Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00309894
Recruitment Status : Completed
First Posted : April 3, 2006
Last Update Posted : August 5, 2019
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of California, San Francisco

Brief Summary:

RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as ketoconazole, may stop the adrenal glands from making androgens. GM-CSF may help ketoconazole work better by making tumor cells more sensitive to the drug. Giving ketoconazole together with hydrocortisone and GM-CSF may be an effective treatment for prostate cancer.

PURPOSE: This phase II trial is studying how well giving ketoconazole together with hydrocortisone and GM-CSF works in treating patients with progressive prostate cancer after hormone therapy.

Condition or disease Intervention/treatment Phase
Prostate Cancer Biological: sargramostim Drug: ketoconazole Drug: therapeutic hydrocortisone Phase 2

Detailed Description:



  • Evaluate the effect of ketoconazole, hydrocortisone, and sargramostim (GM-CSF) on time to clinical progression in patients with prostate cancer that has progressed on primary hormonal therapy.


  • Evaluate the objective response frequency in patients treated with this regimen.
  • Investigate the safety of this regimen.

OUTLINE: This is an open-label, nonrandomized study.

Patients receive oral ketoconazole three times daily and oral hydrocortisone twice daily on days 1-28 and sargramostim (GM-CSF) subcutaneously on days 15-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 48 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 49 participants
Allocation: Non-Randomized
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Trial to Assess the Activity of Ketoconazole Plus GM-CSF in Patients With Prostate Cancer Progressive After Androgen Deprivation
Study Start Date : April 2004
Actual Primary Completion Date : November 2007
Actual Study Completion Date : December 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Primary Outcome Measures :
  1. Time to progression

Secondary Outcome Measures :
  1. Response rate as measured by prostate-specific antigen and objective parameters
  2. Frequency of grades 3-4 toxicity
  3. Pattern of immune response as measured by immunohistochemistry

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 120 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No


  • Histologically confirmed adenocarcinoma of the prostate
  • Progressive disease after androgen deprivation AND meets 1 of the following criteria:

    • Measurable disease

      • Measurable lesions ≥ 10 mm with spiral CT
      • Up to 5 lesions per organ and 10 lesions total should be identified as target lesions
    • No measurable disease

      • Patients with prostate-specific antigen (PSA)-only disease must have an elevated PSA

        • PSA evidence for progressive disease consists of a PSA level of ≥ 5 ng/mL that has risen on ≥ 2 successive occasions, ≥ 2 weeks apart
      • Patients with a positive bone scan must also have an elevated PSA
  • Patients who received prior antiandrogen as a part of primary androgen ablation therapy must demonstrate disease progression after discontinuation of the antiandrogen

    • Disease progression after antiandrogen withdrawal is defined as 2 consecutive rising PSA values obtained ≥ 2 weeks apart, or documented osseous or soft tissue progression

      • Patients receiving flutamide must have had ≥ 1 of the PSA values obtained ≥ 4 weeks after flutamide discontinuation
      • Patients receiving bicalutamide or nilutamide must have had ≥ 1 of the PSA values obtained ≥ 6 weeks after antiandrogen discontinuation
  • Testosterone < 50 ng/dL
  • PSA ≥ 5 ng/mL


  • Karnofsky performance status 60-100%
  • No serious intercurrent infections or nonmalignant uncontrolled medical illnesses
  • No psychiatric illnesses OR social situations that would limit compliance
  • No active or uncontrolled autoimmune disease
  • ALT and AST normal
  • Bilirubin normal
  • Absolute neutrophil count ≥ 1,500/mm³
  • Platelet count ≥ 100,000/mm³
  • Creatinine ≤ 1.5 times upper limit or normal (ULN)
  • Hemoglobin ≥ 8 g/dL
  • No other currently active malignancy except for nonmelanoma skin cancer

    • No currently active malignancy defined as therapy completed with ≤ 30% risk of relapse


  • See Disease Characteristics
  • Patients must continue primary androgen deprivation therapy with a luteinizing-hormone releasing-hormone (LHRH) analogue if they have not undergone orchiectomy
  • No prior systemic chemotherapy for prostate cancer

    • All other systemic chemotherapy must have been completed ≥ 2 years prior to study
  • No other concurrent chemotherapy, immunotherapy, or radiotherapy
  • Major surgery or radiation therapy completed ≥ 4 weeks prior to study
  • No other concurrent corticosteroids, including routine use antiemetics
  • No prior ketoconazole, aminoglutethimide, or corticosteroids for treatment of progressive prostate cancer
  • No prior immunotherapy (e.g., vaccines or sargramostim GM-CSF)
  • Patients receiving any other hormonal therapy (e.g., megestrol, finasteride, herbal product known to decrease PSA levels [e.g., saw palmetto or PC-SPES], or any systemic corticosteroid) must discontinue the agent ≥ 4 weeks prior to enrollment and progressive disease must be documented after discontinuation
  • No initiation of bisphosphonate therapy within 1 month prior to starting study therapy

    • Patients on stable doses that show tumor progression are allowed to continue bisphosphonate
  • No concurrent supplements or complementary medicines/botanicals, except any combination of the following:

    • Conventional multivitamin supplements
    • Selenium
    • Lycopene
    • Soy supplements
    • Vitamin E
  • At least 8 weeks since prior radiopharmaceuticals (strontium chloride Sr 89, samarium Sm 153 lexidronam pentasodium)
  • No other concurrent investigational or commercial anticancer agents or therapies

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00309894

Layout table for location information
United States, California
UCSF Comprehensive Cancer Center
San Francisco, California, United States, 94115
Veterans Affairs Medical Center - San Francisco
San Francisco, California, United States, 94121
Sponsors and Collaborators
University of California, San Francisco
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: Charles Ryan, MD University of California, San Francisco

Layout table for additonal information
Responsible Party: University of California, San Francisco Identifier: NCT00309894     History of Changes
Other Study ID Numbers: 035516
First Posted: April 3, 2006    Key Record Dates
Last Update Posted: August 5, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by University of California, San Francisco:
adenocarcinoma of the prostate
recurrent prostate cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Hydrocortisone 17-butyrate 21-propionate
Genital Diseases, Male
Prostatic Diseases
Hydrocortisone acetate
Hydrocortisone hemisuccinate
Anti-Inflammatory Agents
Antifungal Agents
Anti-Infective Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP3A Inhibitors
Immunologic Factors